

# Fielmann AG

## Germany | Retail | MCap EUR 5.7bn

11 January 2021





# Prelim Q4: Strong finish in Q4; PT up, remains BUY

### What's it all about?

Ahead of schedule, Fielmann released strong prelim. FY 2020 results, beating both our and consensus estimates. An EBT of c. EUR 170m comes in c. 10% above our previous estimate pointing towards a strong Q4 2020. In addition, Fielmann expressed confidence for fiscal 2021 which is backed by the recently acquired Spanish Óptica & Audiología Universitaria as well as a much more resilient business model than it has been at the beginning of the pandemic (mainly due to improved hygiene concepts and online ordering tools). With a solid balance sheet, we expect Fielmann to execute on its Vision 2025 strategy and to resume its dividend payment as soon as FY 2020. Remains BUY with new PT EUR 75.00 (old EUR 72.00)

### BUY (BUY)

**Target price** Current price Up/downside **EUR 75.00** (old 72.00) EUR 68.20 10%

#### MAIN AUTHOR

Thomas Wissler Equity Research Analyst t.wissler@alsterresearch.com +49 40 309 293-52

# IMPORTANT. Please refer to the last page of this report for "Important disclosures" and analyst(s) certifications.

#### alsterresearch.com

This research is the product of AlsterResearch, which is authorised and regulated by the BaFin in Germany.



# Fielmann AG

### Germany | Retail | MCap EUR 5.7bn

BUY (BUY)	<b>Target price</b> Current price Up/downside	<b>EUR 75.00</b> (old 72.00) EUR 68.20 10%	MAIN AUTHOR Thomas Wissler Equity Research Analyst t wissler@alsterresearch.com
			t.wissler@alsterresearch.com +49 40 309 293-52

## Prelim Q4: Strong finish in Q4; PT up, remains BUY

Ahead of its regular results date on Feb. 1, Fielmann released prelim. FY results beating both our and consensus estimates. Despite the extensive restrictions due to the ongoing pandemic, Fielmann expects to have beaten its already upwards revised guidance for FY 2020. According to the company external sales (including VAT and inventory changes) are seen at c. EUR 1.63bn (previous year: EUR 1.74bn). Consolidated sales are expected to stand at EUR 1.43bn (previous year: EUR 1.52bn). EBT will reach nearly EUR 170m (previous year: € 253.8m) and thus approx. 10% ahead of our expectations.

As at the end of 2020, Fielmann operated 870 stores (previous year: 776 stores), including 80 stores of the Spanish optical chain Óptica & Audiología Universitaria acquired on 31 December 2020. The Spanish subsidiary will contribute to the Group's earnings for the first time in FY 2021.

**Outlook**: Fielmann expressed confidence for fiscal year 2021. Despite the economic challenges posed by the restrictions due to the ongoing coronavirus pandemic, Fielmann's business development proves to be resilient and is less affected than it was at the beginning of the pandemic. As such, Fielmann is determined to continue the implementation of its Vision 2025, which includes continued investments to drive the digitization and internationalization of its business model.

**Conclusion**: In our view, the prelim. results once again highlighted the strong competitive quality of Fielmann's business model with returns on average well in excess of 20%. With a financially sound balance sheet (eAR net debt of EUR 20m by FY 2020 before the Óptica acquisition) the company is well equipped to further drive its investment strategy and to resume its dividend payment in 2020E (eAR EUR 1.30). We slightly increase our PT to EUR 75.00 (old: EUR 72.00) and reiterate our BUY recommendation.

Fielmann AG	2017	2018	2019	2020E	2021E	2022E
Sales	1.386	1.428	1.521	1.425	1.609	1.699
Growth yoy	na	3%	6,5%	-6,3%	12,9%	5,6%
EBITDA	297	302	394	293	403	426
EBIT	249	251	256	172	267	282
Net profit	168	169	172	112	178	189
Y/E net debt (net cash)	-263	-226	136	20	-106	-194
Net gearing	-37,9%	-31,8%	18,8%	2,7%	-13,0%	-23,1%
Net debt/EBITDA	-0,9	-0,7	0,3	0,1	-0,3	-0,5
EPS recurring	2,00	2,01	2,05	1,34	2,12	2,25
CPS	3,03	1,89	3,15	2,32	2,19	2,43
DPS	1,85	1,90	0,00	1,30	2,02	2,14
Dividend yield	2,7%	2,8%	0,0%	1,9%	3,0%	3,1%
Gross profit margin	80,0%	79,8%	79,9%	79,9%	79,9%	79,9%
EBITDA margin	21,4%	21,1%	25,9%	20,6%	25,1%	25,1%
EBIT margin	18,0%	17,6%	16,8%	12,1%	16,6%	16,6%
ROCE	32,6%	32,1%	26,4%	14,8%	22,1%	22,4%
EV/sales	3,9	3,9	3,9	4,0	3,5	3,3
EV/EBITDA	18,5	18,3	14,9	19,6	14,0	13,0
EV/EBIT	21,5	21,5	22,2	33,4	21,1	19,6
PER	34,2	33,9	33,3	51,1	32,1	30,4
FCF yield	3,5%	3,5%	4,9%	2,3%	3,6%	3,9%

Source: Company data; AlsterResearch



Source: Company data, AlsterResearch

High/low 52 weeks Price/Book Ratio	76.25 / 41.90 7.78x
Ticker / Symbols	
ISIN	DE0005772206
WKN	577220

FIE:GR

#### Changes in estimates

Bloomberg

		Sales	EBIT	EPS
2020	old	1.396	158	1,21
	Δ	2.1%	9.3%	10%
2021	old	1.580	257	2,04
	Δ	1.8%	3.7%	3,9%
2022	old	1.664	271	2,16
	Δ	2.1%	4.0%	4,2%

#### Key share data

Number of shares: (in m pcs)	84.0
Book value per share: (in €)	8.76
Ø trading volume: (12 months)	56,000

#### **Major shareholders**

Fielmann family	71.6 %
Free Float	28.4 %

#### **Company description**

Fielmann AG is a Germany-based company manufacturer of glasses, contact lenses and related eyewear products. The Company manufactures and sells various spectacles, including bifocal and varifocal optical glasses, sunglasses, spectacle frames and contact lenses. The Company operates in Germany, Switzerland, Luxembourg, the Netherlands and Poland, among others



# Financials

Profit and loss (EUR m)	2018	2019	2020E	2021E	2022E
Sales	1.428	1.521	1.425	1.609	1.699
Sales growth	na	6,5%	-6,3%	12,9%	5,6%
Cost of sales	288	306	286	323	342
Gross profit	1.140	1.215	1.139	1.285	1.358
Sales and marketing	0	0	0	0	0
General and administration	864	851	856	901	952
Research and development	0	0	0	0	0
Other operating income	19	19	14	16	17
Other operating expenses	44	127	124	134	141
EBITDA	302	394	293	403	426
Depreciation	45	129	121	136	144
EBITA	257	265	172	267	282
Amortisation of goodwill and intangible assets	6	9	0	0	0
Impairment charges	0	0	0	0	0
EBIT	251	256	172	267	282
Financial result	0	-2	-2	-2	-3
Recurring pretax income from continuing operations	251	254	170	265	280
Extraordinary income/loss	0	0	0	0	0
Earnings before taxes	251	254	170	265	280
Taxes	77	77	51	79	84
Net income from continuing operations	174	177	119	185	196
Result from discontinued operations (net of tax)	0	0	0	0	0
Net income	174	177	119	185	196
Minority interest	5	5	7	7	7
Net profit (reported)	169	172	112	178	189
Average number of shares	84	84	84	84	84
EPS reported	2,01	2,05	1,34	2,12	2,25

Profit and loss (common size)	2018	2019	2020E	2021E	2022E
Sales	100%	100%	100%	100%	100%
Cost of sales	20%	20%	20%	20%	20%
Gross profit	80%	80%	80%	80%	80%
Sales and marketing	0%	0%	0%	0%	0%
General and administration	61%	56%	60%	56%	56%
Research and development	0%	0%	0%	0%	0%
Other operating income	1%	1%	1%	1%	1%
Other operating expenses	3%	8%	9%	8%	8%
EBITDA	21%	26%	21%	25%	25%
Depreciation	3%	8%	8%	8%	8%
EBITA	18%	17%	12%	17%	17%
Amortisation of goodwill and intangible assets	0%	1%	0%	0%	0%
Impairment charges	0%	0%	0%	0%	0%
EBIT	18%	17%	12%	17%	17%
Financial result	0%	0%	0%	0%	0%
Recurring pretax income from continuing operations	18%	17%	12%	16%	16%
Extraordinary income/loss	0%	0%	0%	0%	0%
Earnings before taxes	18%	17%	12%	16%	16%
Taxes	5%	5%	4%	5%	5%
Net income from continuing operations	12%	12%	8%	12%	12%
Result from discontinued operations (net of tax)	0%	0%	0%	0%	0%
Net income	12%	12%	8%	12%	12%
Minority interest	0%	0%	0%	0%	0%
Net profit (reported)	12%	11%	8%	11%	11%

Source: Company data; AlsterResearch



Balance sheet (EUR m)	2018	2019	2020E	2021E	2022E
Intangible assets	81	118	118	118	118
Property, plant and equipment	262	660	608	541	466
Financial assets	95	59	59	59	59
FIXED ASSETS	439	837	786	719	644
Inventories	136	159	149	168	177
Accounts receivable	102	109	102	116	122
Other current assets	0	0	0	0	0
Liquid assets	248	237	353	479	567
Deferred taxes	0	0	0	0	0
Deferred charges and prepaid expenses	19	25	25	26	27
CURRENT ASSETS	506	529	629	788	893
TOTAL ASSETS	945	1.367	1.414	1.507	1.537
SHAREHOLDERS EQUITY	709	723	736	813	840
MINORITY INTEREST	0	4	4	4	4
Long-term debt	1	297	297	297	297
Provisions for pensions and similar obligations	8	9	9	9	9
Other provisions	49	47	47	47	47
Non-current liabilities	57	352	352	352	352
short-term liabilities to banks	22	76	76	76	76
Accounts payable	56	73	117	132	140
Advance payments received on orders	0	0	0	0	0
Other liabilities (incl. from lease and rental contracts)	88	122	122	122	122
Deferred taxes	12	18	18	18	18
Deferred income	0	0	0	0	0
Current liabilities	144	194	239	254	261
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	945	1.367	1.424	1.517	1.551

Balance sheet (common size)	2018	2019	2020E	2021E	2022E
Intangible assets	9%	9%	8%	8%	8%
Property, plant and equipment	28%	48%	43%	36%	30%
Financial assets	10%	4%	4%	4%	4%
FIXED ASSETS	<b>46</b> %	61%	<b>56</b> %	<b>48</b> %	42%
Inventories	14%	12%	11%	11%	12%
Accounts receivable	11%	8%	7%	8%	8%
Other current assets	0%	0%	0%	0%	0%
Liquid assets	26%	17%	25%	32%	37%
Deferred taxes	0%	0%	0%	0%	0%
Deferred charges and prepaid expenses	2%	2%	2%	2%	2%
CURRENT ASSETS	54%	39%	44%	<b>52</b> %	58%
TOTAL ASSETS	100%	100%	100%	100%	100%
SHAREHOLDERS EQUITY	75%	53%	<b>52</b> %	54%	55%
MINORITY INTEREST	0%	0%	0%	0%	0%
Long-term debt	0%	22%	21%	20%	19%
Provisions for pensions and similar obligations	1%	1%	1%	1%	1%
Other provisions	5%	3%	3%	3%	3%
Non-current liabilities	6%	<b>26</b> %	25%	23%	23%
short-term liabilities to banks	2%	6%	5%	5%	5%
Accounts payable	6%	5%	8%	9%	9%
Advance payments received on orders	0%	0%	0%	0%	0%
Other liabilities (incl. from lease and rental contracts)	9%	9%	9%	8%	8%
Deferred taxes	1%	1%	1%	1%	1%
Deferred income	0%	0%	0%	0%	0%
Current liabilities	15%	14%	17%	17%	17%
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	100%	100%	101%	101%	101%



Cash flow statement (EUR m)	2018	2019	2020E	2021E	2022E
Net profit/loss	251	254	119	185	196
Depreciation of fixed assets (incl. leases)	39	120	121	136	144
Amortisation of goodwill	0	0	0	0	0
Amortisation of intangible assets	6	9	0	0	0
Others	11	10	0	0	0
Cash flow from operations before changes in w/c	307	393	240	322	340
Increase/decrease in inventory	0	0	10	-19	-9
Increase/decrease in accounts receivable	0	0	7	-13	-6
Increase/decrease in accounts payable	0	0	44	15	7
Increase/decrease in other working capital positions	-114	-91	0	0	0
Increase/decrease in working capital	-114	-91	61	-17	-9
Cash flow from operating activities	193	302	301	304	331
CAPEX	61	69	69	69	69
Payments for acquisitions	2	15	0	0	0
Financial investments	3	-19	0	0	0
Income from asset disposals	0	0	0	0	0
Cash flow from investing activities	-65	-65	-69	-69	-69
Cash flow before financing	128	237	232	235	262
Increase/decrease in debt position	-1	-79	0	0	0
Purchase of own shares	1	0	0	0	0
Capital measures	0	0	0	0	0
Dividends paid	160	165	0	109	170
Others	-1	-1	0	0	0
Effects of exchange rate changes on cash	0	0	0	0	0
Cash flow from financing activities	-162	-245	0	-109	-170
Increase/decrease in liquid assets	-33	-8	232	126	92
Liquid assets at end of period	139	131	363	488	580

Source: Company data; AlsterResearch



Ratios	2018	2019	2020E	2021E	2022E
Per share data					
Earnings per share reported	2,01	2,05	1,34	2,12	2,25
Cash flow per share	1,89	3,15	2,32	2,19	2,43
Book value per share	8,44	8,60	8,76	9,68	10,00
Dividend per share	1,90	0,00	1,30	2,02	2,14
Valuation					
P/E	34x	33x	51x	32x	30x
P/CF	36x	22x	29x	31x	28x
P/BV	8,1x	7,9x	7,8x	7,0x	6,8x
Dividend yield (%)	2,8%	0,0%	1,9%	3,0%	3,1%
FCF yield (%)	3,5%	4,9%	2,3%	3,6%	3,9%
EV/Sales	3,9	3,9	4,0	3,5	3,3
EV/EBITDA	18,3	14,9	19,6	14,0	13,0
EV/EBIT	21,5	22,2	33,4	21,1	19,6
Income Statment (EURm)					
Sales	1.428	1.521	1.425	1.609	1.699
yoy chg in %	na	6%	-6%	13%	6%
Gross profit	1.140	1.215	1.139	1.285	1.358
Gross margin in %	80%	80%	80%	80%	80%
EBITDA	302	394	293	403	426
EBITDA margin in %	21%	26%	21%	25%	25%
EBIT	251	256	172	267	282
EBIT margin in %	18%	17%	12%	17%	17%
Net profit	169	172	112	178	189
Cash flow statement					
CF from operations	193	302	301	304	331
Сарех	61	69	69	69	69
Maintenance Capex	35	37	106	120	127
Free cash flow	132	232	232	235	262
Balance sheet (EURm)					
Intangible assets	81	118	118	118	118
Tangible assets	262	660	608	541	466
Shareholders' equity	709	723	736	813	840
Pension provisions	8	9	9	9	9
Liabilities and provisions	79	428	428	428	428
Net financial debt	-226	136	20	-106	-194
w/c requirements	170	189	165	143	155
Ratios					
ROE	24%	24%	15%	22%	22%
ROCE	32%	26%	15%	22%	22%
Net gearing	-32%	19%	3%	-13%	-23%
Net debt / EBITDA	-0,75	0,35	0,07	-0,26	-0,46

Source: Company data; AlsterResearch



# Conflict of interests

Disclosures regarding research publications of SRH AlsterResearch AG pursuant to section 85 of the German Securities Trading Act (WpHG) and distributed in the UK under an EEA branch passport, subject to the FCA requirements on research recommendation disclosures It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. Further to this, under the FCA's rules on research recommendations, any conflicts of interest in connection with the recommendation must be disclosed. A conflict of interest is presumed to exist in particular if SRH AlsterResearch AG

- (1) or its affiliate(s) (either in its own right or as part of a consortium) within the past twelve months, acquired the financial instruments of the analysed company
- (2) has entered into an agreement on the production of the research report with the analysed company,
- (3) or its affiliate(s) has, within the past twelve months, been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement,
- (4) or its affiliate(s) holds a) 5% or more of the share capital of the analysed company, or b) the analysed company holds 5% or more of the share capital of SRH AlsterResearch AG or its affiliate(s),
- (5) or its affiliate(s) holds a net long (a) or a net short (b) position of 0.5% of the outstanding share capital of the analysed company or derivatives thereof,
- (6) or its affiliate(s) is a market maker or liquidity provider in the financial instruments of the issuer,
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company or a significant conflict of interest with respect to the issuer,
- (8) The research report has been made available to the company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

Company	Disclosure
Fielmann AG	0



# Important disclosures

1. General Information/Liabilities This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by SRH AlsterResearch AG, exclusively to selected recipients [in DE, GB, FR, CH, US, UK, Scandinavia, and Benelux or, in individual cases, also in other countries]. A distribution to private investors in the sense of the German Securities Trading Act (WpHG) is excluded. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of SRH AlsterResearch AG. Reproduction of this document, in whole or in part, is not permitted without prior permission SRH AlsterResearch AG. All rights reserved. Under no circumstances shall SRH AlsterResearch AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report - neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

2. Responsibilities This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analyzed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

3. Organisational Requirements SRH AlsterResearch AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of AlsterResearch AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

4. Information Concerning the Methods of Valuation/Update The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow - DCF model. Furthermore, a peer group comparison is made. The adi, FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes. Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjustment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value. SRH AlsterResearch AG uses the following three-step rating system for the analyzed companies: Buy: Sustainable upside potential of more than 10% within 12 months Sell: Sustainable downside potential of more than 10% within 12 months. Hold: Upside/downside potential is limited. No immediate catalyst visible

NB: The ratings of SRH AlsterResearch AG are not based on a performance that is expected to be "relative" to the market.

The decision on the choice of the financial instruments analysed in this document was solely made by SRH AlsterResearch AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of SRH AlsterResearch AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

5. Major Sources of Information Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. SRH AlsterResearch AG has checked the information for plausibility but not for accuracy or completeness.

6. Competent Supervisory Authority SRH AlsterResearch AG are under supervision of the BaFin – German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M. This document is distributed in the UK under a MiFID EEA branch passport and in compliance with the applicable FCA requirements.

7. Specific Comments for Recipients Outside of Germany This research report is subject to the law of the Federal Republic of Germany. The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state.

**8. Miscellaneous** According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: https://www.alsterresearch.com.



# Contacts

SRH AlsterResearch AG Himmelstr . 9 22299 Hamburg

Tel: +49 40 309 293-52 Fax: +49 40 556 330-54 E-Mail: <u>info@alsterresearch.com</u>

Schlöter, Reidock & Herntrich GmbH Leinpfad 100 22299 Hamburg

Tel: +49 40 3785 52- 0 Fax: +49 40 3785 52- 19 E-Mail: info@srh-research.de

mwb fairtrade Wertpapierhandelsbank AG Rottenbucher Straße 28 82166 Gräfeling

Tel: +49 89 85852-0 Fax: +49 89 85852-505 E-Mail: info@mwbfairtrade.com

### Research

OLIVER DREBING Senior Analyst Tel: +49 40 309 293-57 E-Mail: o.drebing@alsterresearch.com

LOUISA HESSELBEIN

Analyst Tel: +49 40 309 293-52 E-Mail: l.hesselbein@alsterresearch.com

KARSTEN RAHLF,CFA

Senior Analyst Tel: +49 40 309 293-54 E-Mail: k.rahlf@alsterresearch.com

ANDREAS SCHÜLER Analyst Tel: +49 40 309 293-55 E-Mail: a.schueler@alsterresearch.com

KATHARINA SCHLÖTER

Analyst Tel: +49 40 309 293-52 E-Mail: k.schloeter@alsterresearch.com

THOMAS WISSLER Senior Analyst Tel: +49 40 309 293-58 E-Mail: t.wissler@alsterresearch.com

ALEXANDER ZIENKOWICZ Analyst Tel: +49 40 309 293-56 E-Mail: a.zienkowicz@alsterresearch.com

### Sales

MARKUS KÖNIG-WEISS Head of Sales Tel: +49 40 309 293-52 E-Mail: mkw@alsterresearch.com

### Sales

CLEMENS SCHLÖTER Senior Sales Tel: +49 40 378 55 211 E-Mail: c.schloeter@srh-research.de

HANS SÜLWALD Sales Tel: +49 40 378 55 235 E-Mail: h.suelwald@srh-research.de

# Equity Capital Markets / Trading

KAI JORDAN Member of the Board Tel: +49 40 36 0995 - 22 E-Mail: kjordan@mwbfairtrade.com

ALEXANDER DEUSS Head of Institutional Sales Tel: +49 40 36 0995- 22 E-Mail: adeuss@mwbfairtrade.com

SASCHA GUENON Head of Designated Sponsoring Tel: +49 40 360 995 - 23 E-Mail: sguenon@mwbfairtrade.com